[
    [
        {
            "time": "2021-Q3",
            "original_text": "华东医药2021三季报点评：“少女针”伊妍士上市放量，整体经营有望企稳向好【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "华东医药",
                    "三季报",
                    "少女针",
                    "伊妍士",
                    "上市放量",
                    "整体经营",
                    "企稳向好"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药2021三季报点评：“少女针”伊妍士上市放量，整体经营有望企稳向好【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "浙商证券维持华东医药买入评级，2021年三季报点评：医美成新引擎，少女针有望超预期",
            "features": {
                "keywords": [
                    "浙商证券",
                    "华东医药",
                    "买入评级",
                    "三季报",
                    "医美",
                    "新引擎",
                    "少女针",
                    "超预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券维持华东医药买入评级，2021年三季报点评：医美成新引擎，少女针有望超预期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "东吴证券维持华东医药买入评级，2021三季报点评：“少女针”伊妍士上市放量，整体经营有望企稳向好",
            "features": {
                "keywords": [
                    "东吴证券",
                    "华东医药",
                    "买入评级",
                    "三季报",
                    "少女针",
                    "伊妍士",
                    "上市放量",
                    "整体经营",
                    "企稳向好"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券维持华东医药买入评级，2021三季报点评：“少女针”伊妍士上市放量，整体经营有望企稳向好",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "天风证券：给予华东医药买入评级，目标价位63.55元",
            "features": {
                "keywords": [
                    "天风证券",
                    "华东医药",
                    "买入评级",
                    "目标价位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天风证券：给予华东医药买入评级，目标价位63.55元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]